Immune‐Mediated Thrombocytopenia in an Ulcerative Colitis Patient After Initiating Filgotinib Treatment: A Case Report [PDF]
Clinical Case ReportsModerate‐to‐severe ulcerative colitis can be effectively treated with JAK‐1 inhibition, but platelet counts should be closely monitored, especially in active disease.
M. J. van derHoff +2 more
doaj +3 more sources
Validated DBS method for filgotinib quantitation in rat dried blood spots and its application to a pharmacokinetic study in rats [PDF]
ADMET and DMPK, 2020 Filgotinib is a selective JAK1 (Janus kinase) inhibitor, showed efficacy in patients suffering from moderate-to-severe rheumatoid arthritis. In this paper, we present the data on the development and validation of a sensitive, selective and high ...
Abhishek Dixit +3 more
doaj +3 more sources
Impact of filgotinib on pain control in the phase 3 FINCH studies [PDF]
RMD OpenObjective This post hoc analysis of the FINCH 1–3 (NCT02889796, NCT02873936 and NCT02886728) studies assessed specific effects of filgotinib on pain control and their relationship with other aspects of efficacy in patients with rheumatoid arthritis (RA).
Bruno Fautrel +12 more
doaj +3 more sources
A disproportionality analysis of FDA adverse event reporting system (FAERS) events for filgotinib. [PDF]
PLoS ONEBackgroundAlthough filgotinib, a selective Janus kinase 1 inhibitor, has been increasingly applied in the treatment of inflammatory diseases, its comprehensive safety profile remains insufficiently characterized.
Yinli Shi +7 more
doaj +2 more sources
Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3 [PDF]
RMD Open, 2021 Objective This analysis evaluated efficacy and safety of filgotinib, a Janus-associated kinase 1-preferential inhibitor, in methotrexate (MTX)-naive patients with rheumatoid arthritis (RA) with multiple poor prognostic factors (PPFs).Methods This was a ...
René Westhovens +8 more
doaj +8 more sources
Janus kinase 1 inhibitors for treating immune checkpoint inhibitor-induced enterocolitis – report of two filgotinib-treated cases and literature review [PDF]
Acta OncologicaBackground and purpose: Treatment of cancer with immune checkpoint inhibitors (ICIs) entails a risk of immune-related adverse events (irAEs). Data on the treatment of immune-related enterocolitis (irEC) in patients with inadequate symptom control after ...
Henrik Ekedahl +5 more
doaj +2 more sources
Rheumatology and Therapy, 2023 Introduction This post hoc analysis of the phase 3 rheumatoid arthritis (RA) filgotinib clinical trial program assessed the effect of filgotinib on body mass index (BMI) in patients with RA and the impact of BMI on the efficacy and safety of filgotinib ...
Alejandro Balsa +11 more
doaj +6 more sources
Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study [PDF]
RMD OpenObjectives DARWIN 3 (ClinicalTrials.gov: NCT02065700) assessed the safety and efficacy of filgotinib in a long-term extension (LTE) of two phase II randomised controlled rheumatoid arthritis (RA) trials.Methods Eligible patients completing the 24-week ...
Arthur Kavanaugh +13 more
doaj +2 more sources
Filgotinib Radiographic and Clinical Efficacy Versus Other JAK Inhibitors and Adalimumab in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Systematic Review and Network Meta-Analysis [PDF]
Rheumatology and TherapyA Bayesian network meta-analysis was conducted to examine the radiographic and clinical efficacy of the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, upadacitinib, and filgotinib and the biologic disease-modifying antirheumatic drug (bDMARD ...
Yoshiya Tanaka +5 more
doaj +2 more sources
Effects of hypnotic bromovalerylurea on microglial BV2 cells [PDF]
Journal of Pharmacological Sciences, 2017 An old sedative and hypnotic bromovalerylurea (BU) has anti-inflammatory effects. BU suppressed nitric oxide (NO) release and proinflammatory cytokine expression by lipopolysaccharide (LPS)-treated BV2 cells, a murine microglial cell line.
Shun Kawasaki +13 more
doaj +3 more sources